Barbara M King

List of Publications by Year in Descending Order

29 papers	620 citations	15 h-index	24 g-index
29 ext. papers	668 ext. citations	4 avg, IF	3.06 L-index

#	Paper	IF	Citations
29	MUCOPOLYSACCHARIDOSIS II (MPS II) IN A FREE-LIVING KAKA (NESTOR MERIDIONALIS) IN NEW ZEALAND. *Journal of Wildlife Diseases*, **2021**, 57, 884-890	1.3	1
28	Is SGSH heterozygosity a risk factor for early-onset neurodegenerative disease?. *Journal of Inherited Metabolic Disease*, **2021**, 44, 763-776	5.4	1
27	AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 174-187	6.4	10
26	Mannosidosis in German Shepherd Dogs. *Veterinary Pathology*, **2019**, 56, 743-748	2.8	3
25	Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions. *ACS Chemical Neuroscience*, **2019**, 10, 3847-3858	5.7	5
24	Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. *Journal of Inherited Metabolic Disease*, **2017**, 40, 443-453	5.4	11
23	A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome. *Journal of Inherited Metabolic Disease*, **2017**, 40, 715-724	5.4	8
22	Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. *Experimental Neurology*, **2016**, 278, 11-21	5.7	11
21	Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. *Journal of Neurochemistry*, **2016**, 137, 409-22	6	13
20	Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice. *Molecular Genetics and Metabolism*, **2015**, 115, 33-40	3.7	20
19	Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. *Journal of Inherited Metabolic Disease*, **2015**, 38, 341-50	5.4	17
18	Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. *Experimental Neurology*, **2015**, 263, 79-90	5.7	24
17	Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. *European Journal of Neuroscience*, **2014**, 39, 2139-50	3.5	12
16	Neonatal Bone Marrow Transplantation in MPS IIIA Mice. *JIMD Reports*, **2013**, 8, 121-32	1.9	18
15	Treatment of canine fucosidosis by intracisternal enzyme infusion. *Experimental Neurology*, **2011**, 230, 218-26	5.7	23
14	Enzyme replacement reduces neuropathology in MPS IIIA dogs. *Neurobiology of Disease*, **2011**, 43, 422-34	7.5	43
13	Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. *European Journal of Neuroscience*, **2009**, 29, 1197-214	3.5	58

12	Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study. *Molecular Genetics and Metabolism*, **2009**, 98, 383-92	3.7	50
11	Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. *Molecular Genetics and Metabolism*, **2007**, 90, 313-28	3.7	75
10	Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. *Brain Research*, **2006**, 1104, 1-17	3.7	79
9	Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. *Molecular Genetics and Metabolism*, **2006**, 87, 107-12	3.7	27
8	Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. *Molecular Genetics and Metabolism*, **2006**, 89, 48-57	3.7	18
7	Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations. *Journal of Molecular Neuroscience*, **2004**, 24, 277-91	3.3	7
6	Purification and characterization of recombinant human lysosomal alpha-mannosidase. *Molecular Genetics and Metabolism*, **2001**, 73, 18-29	3.7	24
5	Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. *Journal of Molecular Neuroscience*, **2000**, 15, 251-62	3.3	16
4	Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat. *Journal of Molecular Neuroscience*, **1998**, 11, 223-32	3.3	6
3	Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1998**, 1407, 163-72	6.9	10
2	Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1997**, 1361, 203-16	6.9	28
1	Sulfate transport in normal and cystic fibrosis fibroblasts. *Biochemical Medicine and Metabolic Biology*, **1992**, 47, 260-4		2